

# Selenium and Sex Steroid Hormones in a U.S. Nationally Representative Sample of Men: A Role for the Link between Selenium and Estradiol in Prostate Carcinogenesis?



Mieke Van Hemelrijck<sup>1</sup>, Sam Sollié<sup>1</sup>, William G. Nelson<sup>2</sup>, James D. Yager<sup>2</sup>, Norma F. Kanarek<sup>2</sup>, Adrian Dobs<sup>3</sup>, Elizabeth A. Platz<sup>4</sup>, and Sabine Rohrmann<sup>5</sup>

## Abstract

**Background:** Given the recent findings from pooled studies about a potential inverse association between selenium levels and prostate cancer risk, this cross-sectional study aimed to investigate the association between serum selenium and serum concentrations of sex steroid hormones including estradiol in a nationally representative sample of U.S. men to investigate one mechanism by which selenium may influence prostate cancer risk.

**Methods:** The study included 1,420 men ages 20 years or older who participated in the Third National Health and Nutrition Examination Survey between 1988 and 1994. We calculated age/race-ethnicity-adjusted and multivariable-adjusted geometric mean serum concentrations of total and estimated free testosterone and estradiol, androstenediol glucuronide, and sex hormone binding globulin, and compared them across quartiles of serum selenium.

**Results:** Adjusting for age, race/ethnicity, smoking status, serum cotinine, household income, physical activity,

alcohol consumption, and percent body fat, mean total estradiol [e.g., Q1, 38.00 pg/mL (95% confidence interval (CI), 36.03–40.08) vs. Q4, 35.29 pg/mL (95% CI, 33.53–37.14);  $P_{\text{trend}} = 0.050$ ] and free estradiol [e.g., Q1, 0.96 pg/mL (95% CI, 0.92–1.01) vs. Q4, 0.90 (95% CI, 0.85–0.95);  $P_{\text{trend}} = 0.065$ ] concentrations decreased over quartiles of selenium. Stratification by smoking and alcohol consumption, showed that the latter observation was stronger for never smokers ( $P_{\text{interaction}} = 0.073$ ) and those with limited alcohol intake ( $P_{\text{interaction}} = 0.017$ ). No associations were observed for the other sex steroid hormones studied.

**Conclusions:** Our findings suggests that a possible mechanism by which selenium may be protective for prostate cancer is related to estrogen.

**Impact:** Further studies of longitudinal measurements of serum and toenail selenium in relation to serum measurements of sex steroid hormones are needed.

## Introduction

A recent Cochrane review indicated that findings for the potential antitumorigenic effects of selenium are inconsistent (1). In the context of prostate cancer, they identified 17 epidemiologic studies, for which the summary OR was 0.79 [95% confidence interval (CI), 0.69–0.90] when comparing higher selenium exposure to lower. When stratifying by method of selenium assessment, an

inverse association with prostate cancer risk was observed for higher baseline biomarkers (OR, 0.76; 95% CI, 0.67–0.88), but not for higher estimated dietary selenium intake (OR, 1.00; 95% CI, 0.73–1.36). Among the selenium biomarkers, the inverse association was stronger for toenail (OR, 0.53; 95% CI, 0.35–0.81) than blood (OR, 0.82; 95% CI, 0.72–0.93) levels (1). Recent findings of the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group, which pooled primary data from prospective studies, corroborated this observation, noting that toenail selenium was inversely associated with total prostate cancer (OR, 0.29; 95% CI, 0.22–0.40), but not blood selenium (2).

Some randomized controlled trials (RCT) have also observed beneficial effects of selenium supplements on prostate cancer risk as a secondary outcome (3, 4). In an RCT of 974 men with a history of either basal cell or squamous cell carcinoma who were randomized to either a daily supplement of 200 µg of selenium or placebo, Clarke and colleagues showed that selenium was associated with 63% reduction in prostate cancer risk ( $P = 0.002$ ), but not the primary outcome of recurrent skin cancer (4). A secondary analysis of this RCT observed that significant reductions in prostate cancer risk were only observed for those with selenium concentrations <123.3 ng/mL (lowest two tertiles; ref. 5). In contrast, the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a large RCT designed specifically to investigate selenium supplementation in the prevention of prostate cancer, did not

<sup>1</sup>King's College London, School of Cancer and Pharmaceutical Sciences, Translational Oncology and Urology Research (TOUR), London, United Kingdom.

<sup>2</sup>Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. <sup>3</sup>Division of Endocrinology, Diabetes and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland. <sup>4</sup>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. <sup>5</sup>Department of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland.

**Corresponding Authors:** Sabine Rohrmann, University of Zurich, Hirschengraben 84, Zürich 8001, Switzerland. Phone: 414-4634-5256; Fax: 414-4634-4909; E-mail: sabine.rohrmann@ifspm.uzh.ch; and Mieke Van Hemelrijck, King's College London, London SE1 9RT, United Kingdom. Phone: 4402-0718-85594; E-mail: mieke.vanhemelrijck@kcl.ac.uk

doi: 10.1158/1055-9965.EPI-18-0520

©2018 American Association for Cancer Research.

show a benefit (6), including in men with lower baseline toenail selenium status (7).

The biological mechanisms underlying a potential protective effect of selenium for cancer are not well understood. One mechanism suggested to explain a link between selenium and prostate cancer, is genetic variation in selenoproteins and related antioxidant enzymes (8). Another more recently suggested hypothesis is focused on a link with sex steroid hormones. For example, even though estrogen therapy was historically used to decrease androgen levels of men with advanced prostate cancer, recent studies suggest a role in prostate carcinogenesis. Estrogen has been shown to induce neoplastic epithelial morphology in both human and rat prostates and to regulate prostate-specific gene expression. Antiestrogens have also been shown to inhibit development and progression of prostate cancer under experimental and clinical conditions (9).

Given the growing evidence for a role of estrogen in prostate cancer carcinogenesis (10), it is of interest to also investigate selenium action in relation to prostate cancer risk. For example, it is hypothesized that the progressive emergence of the estrogen receptor  $\alpha$  (ER $\alpha$ ) during prostate cancer progression and hormone refractory disease presents a mechanism through which the tumor can bypass androgens using estrogen and progesterone. Nevertheless, few studies have investigated the link between selenium and other sex steroid hormones such as testosterone and sex hormone binding globulin (SHBG); no clear associations have been observed to date (11, 12).

If underlying biological mechanisms were better understood, they may inform the current inconsistency among studies and trials addressing selenium and risk of cancer, especially prostate cancer. Hence, in this cross-sectional study, we investigated the association between serum selenium and serum concentrations of sex steroid hormones including estradiol in a nationally representative sample of U.S. men to inform one mechanism by which selenium may influence prostate cancer risk.

## Materials and Methods

### Study population

The Third National Health and Nutrition Examination Survey (NHANES III) was conducted by the National Center for Health Statistics (NCHS) between 1988 and 1994 (13) and designed as a multistage stratified, clustered probability sample of the U.S. civilian noninstitutionalized population who was at least 2 months old. All participants were interviewed at home and underwent an extensive physical examination, including a blood sample performed at a mobile examination center (13). NHANES III was conducted in two phases (1988–1991 and 1991–1994), which both lead to independent unbiased national estimates of health and nutrition characteristics. Within each phase, participants were randomly assigned to enter either the morning or afternoon/evening examination session. Of the 2,205 men, who took part in the morning session of phase I (1988–1991), we selected all men ages 20+ years with no history of prostate cancer, who had serum total testosterone, total estradiol, SHBG, androstenediol glucuronide (AAG), as well serum selenium measured ( $n = 1,420$ ).

### Hormone measurements

Sex steroid hormones were assayed using stored serum samples at Children's Hospital (Boston, MA). Competitive electrochemi-

luminescence immunoassays on the 2010 Elecsys Autoanalyzer (Roche Diagnostics) were used to measure testosterone, estradiol, and SHBG concentrations in 2005. AAG, an indicator of the conversion of testosterone to dihydrotestosterone, was assessed with an Enzyme Immunoassay (Diagnostic Systems Laboratories). Laboratory technicians were blinded to participant characteristics. These assays had the following detection limits for testosterone, estradiol, AAG, and SHBG: 0.02 ng/mL, 5 pg/mL, 0.33 ng/mL, and 3 nmol/L, respectively. The coefficients of variation for quality control specimens were measured for two or three concentrations each: 5.9% and 5.8% at 2.5 and 5.5 ng/mL for testosterone; 2.5%, 6.5%, and 6.7% at 39.4, 102.7, and 474.1 pg/mL for estradiol; 9.5% and 5.0% at 2.9 and 10.1 ng/mL for AAG; and 5.3% and 5.9% at 5.3 and 16.6 nmol/L for SHBG. The interassay coefficient of variation for quality control samples with a mean estradiol concentration of 39.4 pg/mL (within the typical range for adult males) was 2.5% (14). Predefined formulas were used to estimate free testosterone and estradiol using each man's total testosterone and SHBG concentrations, along with the population normal albumin concentration in men (15, 16).

### Exposure measurements and covariates

Serum selenium concentrations were measured in venous blood samples taken during the NHANES examinations using atomic absorption spectrometry (17). Information on age, race/ethnicity, income, cigarette smoking, and physical activity was collected by interview. The following activities were used to define vigorous physical activity: jogging or running; swimming or aerobics (for men 40 years or older); biking, dancing, gardening, and calisthenics (for men 65 years or older); and walking and lifting weights (for men 80 years or older). Frequency of alcohol consumption was measured by a food frequency questionnaire and categorized by times per week. Percent body fat was estimated from anthropometric and bioelectrical impedance data using the equations of Chumlea and colleagues (18). Serum cotinine levels were measured as described previously (19).

The protocols for the conduct of NHANES III were approved by the Institutional Review Board of the NCHS, Centers for Disease Control and Prevention (Atlanta, GA). All participants provided written informed consent. The assay of stored serum specimens for the Hormone Demonstration Program was approved by the Institutional Review Boards at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD) and the NCHS, Centers for Disease Control and Prevention (Atlanta, GA).

### Statistical analysis

We used phase I morning sampling weights for NHANES III to account for sampling variability and adjust for differential probability of selection of persons (13). Age-adjusted means or percentages of characteristics of the men by quartiles of serum selenium concentration were calculated after adjusting for the age distribution of the U.S. population according to the 2000 Census. Next, we calculated adjusted geometric mean concentrations of the sex steroid hormones and their 95% CIs by quartiles of serum selenium using linear regression. As the hormone concentrations were not normally distributed, we used log transformations. Multivariable models were adjusted for age (continuous), race/ethnicity, and factors that have been associated with hormone concentrations in previous NHANES III analyses: cigarette smoking (never, former, and current), serum cotinine (continuous), household income (<\$20,000 and  $\geq$ \$20,000),

vigorous physical activity (yes or no), alcohol intake (0, <2, 2–3, 4–6 times a week, or daily or more), and percent body fat (continuous).

For those sex steroid hormones for which the multivariable models indicated a trend across selenium quartiles, we conducted further stratified analyses. Specifically, we assessed whether age (20–40, 40–60, and 60+ years), race/ethnicity (non-Hispanic white, non-Hispanic black, Mexican-American, and other), smoking status (never, former, and current), or alcohol consumption (never, <2, and 2+ drinks per week) modified the association between serum selenium and sex steroid hormones. Given the strong potential for confounding by smoking and alcohol drinking, we investigated the association between sex steroid hormones and selenium within never smokers and those with limited alcohol consumption (<2 drinks per week). Interaction was assessed by adding an interaction term and testing its coefficient using the Wald test.

All statistical analyses were conducted with SAS release 9.2 (SAS Institute) and SUDAAN 9.0 software as implemented in SAS 9.2.

## Results

In this sample of men 20+ years old in NHANES III, those with selenium levels  $\geq 122$  ng/mL (i.e., third and fourth quartile) were more likely to be non-Hispanic white, to be never smokers, and to participate in vigorous physical activity (only those with selenium levels  $\geq 133$  ng/mL), as compared with those with selenium levels <122 ng/mL (Table 1). More specifically, those with selenium levels < 122 ng/mL were more likely to be non-Hispanic black, to be smokers, to have lower household income, to have a higher percent body fat, but drink fewer alcoholic drinks (Table 1).

Adjusting for age and race/ethnicity, mean total and free estradiol concentrations were statistically significantly lower in men with higher selenium concentrations (Table 2). These differences in total and free estradiol levels were attenuated, but remained statistically significant after further adjustment for smoking status, cotinine levels, alcohol consumption, physical

activity, income, and percent body fat. This inverse association was also observed for the estradiol/total testosterone ratio, but no associations were observed for total or free testosterone, AAG, and SHBG and serum selenium in these multivariate models (Table 2).

Estradiol decreased across quartiles of serum selenium in both non-Hispanic black and white (Table 3). However, this trend was not statistically significant, and also less obvious for Mexican-American men and men of other race/ethnicities. The inverse association between estradiol and selenium was only apparent among never smokers ( $P_{\text{interaction}} = 0.073$ ), and those who drank <2 alcoholic drinks per week ( $P_{\text{interaction}} = 0.017$ ). In addition, the inverse association between estradiol and selenium was most notable in those aged 60+ years ( $P_{\text{interaction}} = 0.618$ ).

## Discussion

In this nationally representative sample of U.S. men, we observed that mean total estradiol and free estradiol concentrations decreased over quartiles of selenium. Stratification by smoking and alcohol consumption showed that the latter observation was stronger for never smokers and those with limited alcohol intake.

Selenium is required for normal thyroid function, but its link with the balance of sex steroid hormone levels remains to be defined (12, 20). While the studies by Zengt and colleagues (20) and Rotter and colleagues (12) did not find any associations, a study investigating the association between serum levels of testosterone and selenium in infertile men attending a fertility clinic in south-east Nigeria, found a strong positive association (21). However, in the context of development of cancer, our finding of an inverse association between selenium and estradiol is in line with previous animal studies for breast cancer (22). Lee and colleagues investigated the effect of selenium on ER expression and activation using methylselenic acid, an active form of selenium in human breast cancer cells (22). Selenium was found to decrease expression of ER $\alpha$  mRNA and protein and increased

**Table 1.** Age-adjusted participant characteristics<sup>a</sup> by quartile of serum selenium

	Quartile 1, <112 ng/mL	Quartile 2, 112–122 ng/mL	Quartile 3, 122–133 ng/mL	Quartile 4, $\geq 133$ ng/mL
Age, years	45.46 (0.38)	46.02 (0.46)	45.63 (0.50)	45.32 (0.47)
Race–Ethnicity (%)				
Non-Hispanic white	76.04	75.08	80.51	79.97
Non-Hispanic black	15.08	13.46	5.71	5.73
Mexican-American	4.74	5.91	4.33	3.81
Other	4.12	5.56	9.45	10.48
Cigarette smoking (%)				
Never	27.11	29.28	36.26	39.94
Former	26.84	28.94	31.98	35.55
Current	46.16	41.79	31.77	24.51
Serum cotinine (27), ng/mL (%)	158.36 (14.77)	100.04 (10.96)	71.84 (9.24)	85.41 (7.74)
<3.08	46.26	51.68	61.21	64.53
3.08–15	1.44	3.73	3.43	1.44
$\geq 15$	52.30	44.60	35.36	34.03
Income <\$20k, %	38.95	31.38	25.56	26.40
Alcohol consumption (%)				
Never	43.40	31.01	27.33	26.06
Up to once a week	15.47	19.50	20.21	14.50
2–3 times a week	15.71	14.83	18.69	18.33
4–6 times a week	9.32	18.61	18.03	19.82
Daily or more	16.20	16.05	15.44	21.30
Vigorous physical activity (%)	14.95	11.63	14.69	15.81
Percent body fat (%)	22.50 (1.09)	21.79 (0.59)	21.97 (0.76)	21.02 (0.55)

<sup>a</sup>Mean (SE) or percentage.

**Table 2.** Adjusted geometric means (95% CI) by quartile of serum selenium

	Quartile 1, <112 ng/mL	Quartile 2, 112-122 ng/mL	Quartile 3, 122-133 ng/mL	Quartile 4, ≥133 ng/mL	P <sub>trend</sub>
Total testosterone, ng/mL					
Age- and race-ethnicity adjusted	5.09 (4.67-5.55)	5.03 (4.75-5.34)	5.14 (4.91-5.39)	5.02 (4.72-5.34)	0.901
Multivariable model 1 <sup>a</sup>	4.94 (4.54-5.37)	4.95 (4.68-5.23)	5.17 (4.94-5.41)	5.15 (4.88-5.44)	0.122
Multivariable model 2 <sup>b</sup>	5.06 (4.65-5.50)	4.96 (4.73-5.20)	5.20 (4.00-5.41)	5.12 (4.86-5.39)	0.625
Total estradiol, pg/mL					
Age- and race-ethnicity adjusted	39.32 (37.08-41.69)	36.42 (34.55-38.38)	34.59 (33.29-35.94)	34.28 (32.36-36.30)	0.002
Multivariable model 1 <sup>a</sup>	38.19 (36.31-37.59)	35.84 (34.17-37.59)	34.88 (33.62-36.19)	35.18 (33.36-37.10)	0.038
Multivariable model 2 <sup>b</sup>	38.00 (36.03-40.08)	36.10 (34.44-37.84)	35.25 (34.06-36.49)	35.29 (33.53-37.14)	0.050
SHBG, nmol/L					
Age- and race-ethnicity adjusted	36.61 (33.59-40.03)	33.98 (33.49-36.75)	34.40 (32.35-36.59)	34.83 (32.86-36.92)	0.550
Multivariable model 1 <sup>a</sup>	35.96 (32.90-39.30)	33.77 (31.22-36.54)	34.54 (32.39-36.84)	35.20 (33.27-37.24)	0.945
Multivariable model 2 <sup>b</sup>	36.85 (34.37-39.51)	33.67 (31.43-36.06)	34.38 (32.49-36.59)	34.66 (32.99-36.42)	0.351
Androstenediol glucuronide, ng/mL					
Age- and race-ethnicity adjusted	11.65 (10.07-13.49)	12.19 (11.43-13.01)	11.46 (10.64-12.34)	11.62 (11.03-12.24)	0.705
Multivariable model 1 <sup>a</sup>	11.83 (10.24-13.66)	12.25 (11.50-13.04)	11.44 (10.58-12.37)	11.53 (10.88-12.22)	0.490
Multivariable model 2 <sup>b</sup>	11.88 (10.30-13.70)	12.39 (11.58-13.25)	11.50 (10.65-12.43)	11.58 (10.91-12.29)	0.465
Estimated free testosterone, ng/mL					
Age- and race-ethnicity adjusted	0.10 (0.09-0.11)	0.10 (0.10-0.11)	0.10 (0.10-0.11)	0.10 (0.09-0.11)	0.973
Multivariable model 1 <sup>a</sup>	0.10 (0.09-0.11)	0.10 (0.10-0.10)	0.10 (0.10-0.11)	0.10 (0.10-0.11)	0.269
Multivariable model 2 <sup>b</sup>	0.10 (0.09-0.11)	0.10 (0.10-0.10)	0.10 (0.10-0.11)	0.10 (0.10-0.11)	0.390
Estimated free estradiol, pg/mL					
Age- and race-ethnicity adjusted	1.00 (0.94-1.07)	0.94 (0.89-0.99)	0.88 (0.84-0.92)	0.87 (0.82-0.93)	0.003
Multivariable model 1 <sup>a</sup>	0.97 (0.93-1.03)	0.93 (0.88-0.98)	0.89 (0.85-0.93)	0.89 (0.85-0.95)	0.023
Multivariable model 2 <sup>b</sup>	0.96 (0.92-1.01)	0.93 (0.88-0.98)	0.90 (0.86-0.94)	0.90 (0.85-0.95)	0.065
Estradiol × 1000/total testosterone					
Age- and race-ethnicity adjusted	8.17 (7.45-8.96)	7.65 (7.09-8.24)	7.11 (6.74-7.51)	7.22 (6.66-7.82)	0.031
Multivariable model 1 <sup>a</sup>	8.18 (7.42-9.02)	7.66 (7.09-8.27)	7.13 (6.76-7.53)	7.22 (6.71-7.77)	0.029
Multivariable model 2 <sup>b</sup>	7.95 (7.19-8.80)	7.70 (7.17-8.26)	7.17 (6.80-7.56)	7.29 (6.84-7.77)	0.086

<sup>a</sup>Adjusted for age and race-ethnicity, smoking status, and serum cotinine.

<sup>b</sup>Adjusted for variables in model 1 and household income, physical activity, alcohol consumption, and percent body fat.

ERβ mRNA expression in this *in vitro* study. This differential regulation of ERα and ERβ in breast cancer cells has been proposed as a novel mechanism of selenium action in the context of breast cancer prevention (22). In the context of prostate cancer, the mechanism of action remains to be determined. Only one study has investigated the association between selenium and estradiol in the context of prostate cancer, but no association was found (23). However, several experimental studies support the observation that estrogens might play a role in prostatic carcinogenesis (24, 25).

Even though we observed an inverse association between selenium and estradiol across racial/ethnic groups in NHANES, the higher estradiol concentration in non-Hispanic black men compared with non-Hispanic white men supports the known higher risk of prostate cancer in black men (14). The findings for the stratifications by smoking behavior, alcohol consumption, and age require further biological studies as it is unclear why the associations were stronger in the nonsmokers, those with limited alcohol consumption, and those of older age.

**Table 3.** Sensitivity and stratified analyses for the adjusted geometric mean of total estradiol (ng/mL; 95% CI) by quartile of serum selenium

	Quartile 1, <112 ng/mL	Quartile 2, 112-122 ng/mL	Quartile 3, 122-133 ng/mL	Quartile 4, ≥133 ng/mL	P <sub>trend</sub>
Race/ethnicity stratification ( $P_{interaction} = 0.910$ )					
Non-Hispanic white	37.77 (35.31-40.41)	35.56 (33.52-37.73)	34.56 (33.18-35.99)	35.06 (32.86-37.40)	0.145
Non-Hispanic black	43.10 (40.05-46.39)	40.78 (38.73-42.95)	40.30 (37.77-42.99)	39.25 (36.60-42.09)	0.121
Mexican-American	34.52 (33.66-35.41)	33.01 (30.69-35.51)	33.69 (30.88-36.76)	34.70 (32.11-37.49)	0.617
Other	35.91 (29.66-43.48)	37.39 (31.91-43.80)	38.07 (33.47-43.31)	34.42 (29.69-38.89)	0.637
Smoking ( $P_{interaction} = 0.073$ )					
Never	37.31 (35.47-39.25)	33.16 (30.19-36.42)	31.93 (29.56-34.38)	31.65 (28.91-34.64)	0.002
Former	34.21 (30.54-38.32)	32.99 (30.54-38.32)	32.36 (30.23-34.65)	33.61 (31.72-35.62)	0.887
Current	37.31 (35.47-39.25)	33.16 (30.19-36.42)	31.93 (29.56-34.48)	31.65 (28.91-34.64)	0.579
Alcohol consumption ( $P_{interaction} = 0.017$ )					
Never	37.75 (35.67-39.96)	35.43 (32.96-38.09)	34.62 (32.83-36.50)	34.51 (31.48-37.82)	0.059
Up to once a week	38.42 (36.01-40.99)	36.79 (34.21-39.56)	34.87 (32.41-37.51)	33.34 (29.31-37.92)	0.086
≥2 times a week	38.18 (34.88-41.78)	36.42 (34.44-38.51)	35.41 (33.63-37.27)	36.29 (34.74-37.90)	0.345
Age stratification ( $P_{interaction} = 0.612$ )					
20-40	38.81 (36.29-41.50)	37.85 (35.22-40.67)	37.07 (35.54-38.67)	36.70 (34.51-39.03)	0.287
40-60	36.32 (33.95-38.86)	35.29 (33.33-37.36)	33.80 (31.68-36.08)	34.31 (31.80-37.02)	0.211
60+	37.97 (34.81-41.43)	32.52 (29.85-35.43)	33.52 (30.83-36.43)	33.05 (30.37-35.97)	0.083

NOTE: All models are adjusted for age, race-ethnicity, smoking status, serum cotinine, household income, physical activity, alcohol consumption, and percent body fat unless model is restricted or stratified by one of these covariates.

This is one of the largest studies assessing the concentrations of sex steroid hormones in relation to selenium. The sampling design of NHANES makes our findings applicable to the U.S. population of civilian noninstitutionalized men ages 20 years and older. We were also able to adjust for a wide range of potential confounding factors including lifestyle factors and race/ethnicity. As our study is a cross-sectional evaluation of the link between sex steroid hormones and selenium and it was not possible to assess temporality. Studies on sex steroid hormones are limited by high level of the intersubject and intrasubject variability in the production, circulating levels, and metabolic clearance rates of steroid hormones resulting from changes in the diurnal rhythm. Here, we aimed to minimize the influence of variation resulting from diurnal production of the hormones by selecting participants with morning samples. Another limitation of this study is the lack of information on selenium concentrations in toenails, as the association with prostate cancer risk has been shown to vary based on selenium measurements (2). The data collection prior to implementation of PSA testing may also have resulted in the lack of prostate cancer diagnosis for some men, although these are thought to be indolent cancers (26).

### Conclusion

This cross-sectional study suggests that a possible mechanism by which selenium may be protective for prostate cancer is related to estrogen. Further studies of longitudinal measurements of serum and toenail selenium in relation to serum measurements of sex steroid hormones are needed. These studies would also benefit from having more detailed data on PSA measurements as well as prostate biopsy tissue.

### References

- Vinceti M, Dennert G, Crespi CM, Zwahlen M, Brinkman M, Zeegers MP, et al. Selenium for preventing cancer. *Cochrane Database Syst Rev* 2014;3: CD005195.
- Allen NE, Travis RC, Appleby PN, Albanes D, Barnett MJ, Black A, et al. Selenium and prostate cancer: analysis of individual participant data from fifteen prospective studies. *J Natl Cancer Inst* 2016;108:djw153.
- Nicastro HL, Dunn BK. Selenium and prostate cancer prevention: insights from the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Nutrients* 2013;5:1122–48.
- Clark LC, Dalkin B, Krongrad A, Combs GF Jr, Turnbull BW, Slate EH, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. *Br J Urol* 1998;81:730–4.
- Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. *BJU Int* 2003;91:608–12.
- Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 2009;301:39–51.
- Kristal AR, Darke AK, Morris JS, Tangen CM, Goodman PJ, Thompson IM, et al. Baseline selenium status and effects of selenium and vitamin E supplementation on prostate cancer risk. *J Natl Cancer Inst* 2014;106: djt456.
- Gerstenberger JP, Bauer SR, Van Blarigan EL, Sosa E, Song X, Witte JS, et al. Selenoprotein and antioxidant genes and the risk of high-grade prostate cancer and prostate cancer recurrence. *Prostate* 2015;75:60–9.
- Mishra S, Tai Q, Gu X, Schmitz J, Poullard A, Fajardo RJ, et al. Estrogen and estrogen receptor alpha promotes malignancy and osteoblastic tumorigenesis in prostate cancer. *Oncotarget* 2015;6:44388–402.
- Bonkhoff H. Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. *Prostate* 2018;78:2–10.
- El-Bayoumy K, Richie JP Jr, Boyiri T, Komninou D, Prokopczyk B, Trushin N, et al. Influence of selenium-enriched yeast supplementation on biomarkers of oxidative damage and hormone status in healthy adult males: a clinical pilot study. *Cancer Epidemiol Biomarkers Prev* 2002;11:1459–65.
- Rotter I, Kosik-Bogacka DI, Dolegowska B, Safranow K, Kuczynska M, Laszczyńska M. Analysis of the relationship between the blood concentration of several metals, macro- and micronutrients and endocrine disorders associated with male aging. *Environ Geochem Health* 2016; 38:749–61.
- National Center for Health Statistics. Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. *Vital Health Stat* 1. 1994. Available from: [http://www.nber.org/nhanes/nhanes-III/docs/nchs/manuals/pla\\_nop.pdf](http://www.nber.org/nhanes/nhanes-III/docs/nchs/manuals/pla_nop.pdf).
- Rohrmann S, Nelson WG, Rifai N, Brown TR, Dobs A, Kanarek N, et al. Serum estrogen, but not testosterone, levels differ between black and white men in a nationally representative sample of Americans. *J Clin Endocrinol Metab* 2007;92:2519–25.
- Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. *Cancer Epidemiol Biomarkers Prev* 2002;11:1065–71.
- Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab* 1999;84:3666–72.
- Eaton CB, Abdul Baki AR, Waring ME, Roberts MB, Lu B. The association of low selenium and renal insufficiency with coronary heart disease and all-cause mortality: NHANES III follow-up study. *Atherosclerosis* 2010;212:689–94.

### Disclaimer

The content of this work is solely the responsibility of the authors and does not necessarily represent the official views of the Maryland Department of Health or the NIH.

### Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

### Authors' Contributions

**Conception and design:** M. Van Hemelrijck, W.G. Nelson, J.D. Yager, E.A. Platz, S. Rohrmann

**Development of methodology:** M. Van Hemelrijck, S. Rohrmann  
**Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.):** M. Van Hemelrijck, E.A. Platz, S. Rohrmann

**Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis):** M. Van Hemelrijck, S. Rohrmann

**Writing, review, and/or revision of the manuscript:** M. Van Hemelrijck, S. Sollie, W.G. Nelson, N.F. Kanarek, E.A. Platz, S. Rohrmann

**Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases):** S. Rohrmann

**Study supervision:** S. Rohrmann

### Acknowledgments

This is the 15th paper from the Hormone Demonstration Program funded by the Maryland Cigarette Restitution Fund at Johns Hopkins (to W.G. Nelson). This work was also supported by NCI P30 CA006973 (to W.G. Nelson).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 9, 2018; revised July 25, 2018; accepted November 14, 2018; published first November 27, 2018.

18. Chumlea WC, Guo SS, Kuczmarski RJ, Flegal KM, Johnson CL, Heymsfield SB, et al. Body composition estimates from NHANES III bioelectrical impedance data. *Int J Obes Relat Metab Disord* 2002;26:1596–609.
19. Jarvis MJ, Giovino GA, O'Connor RJ, Kozlowski LT, Bernert JT. Variation in nicotine intake among U.S. cigarette smokers during the past 25 years: evidence from NHANES surveys. *Nicotine Tob Res* 2014;16:1620–8.
20. Zeng Q, Zhou B, Feng W, Wang YX, Liu AL, Yue J, et al. Associations of urinary metal concentrations and circulating testosterone in Chinese men. *Reprod Toxicol* 2013;41:109–14.
21. Oluboyo AO, Adijeh RU, Onyenekwe CC, Oluboyo BO, Mbaeri TC, Odiogwu CN, et al. Relationship between serum levels of testosterone, zinc and selenium in infertile males attending fertility clinic in Nnewi, south east Nigeria. *Afr J Med Med Sci* 2012;41:51–4.
22. Lee SO, Nadiminty N, Wu XX, Lou W, Dong Y, Ip C, et al. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells. *Cancer Res* 2005;65:3487–92.
23. Ozten N, Schlicht M, Diamond AM, Bosland MC. L-selenomethionine does not protect against testosterone plus 17beta-estradiol-induced oxidative stress and preneoplastic lesions in the prostate of NBL rats. *Nutr Cancer* 2014;66:825–34.
24. Harkonen PL, Makela SI. Role of estrogens in development of prostate cancer. *J Steroid Biochem Mol Biol* 2004;92:297–305.
25. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. *Nat Rev Cancer* 2007;7:256–69.
26. Verbeek JFM, Roobol MJ, ERSPC Rotterdam Study Group. What is an acceptable false negative rate in the detection of prostate cancer? *Transl Androl Urol* 2018;7:54–60.